| Titre : | Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. (2001) |
| Auteurs : | Joel BLOSTEIN ; Patricia-A CLARK |
| Type de document : | Article |
| Dans : | Public health reports (vol. 116, n° 2, 2001) |
| Pagination : | 165-168 |
| Langues: | Anglais |
| Mots-clés : | Hépatite virale B ; Virose ; Infection ; Dépistage ; Adolescent ; Homme ; Prise de risque ; Analyse coût efficacité ; Economie santé ; Vaccination ; Age ; Etats Unis ; Amérique ; Prévention santé ; Appareil digestif [pathologie] ; Foie [pathologie] ; Amérique du Nord |
| Résumé : | [BDSP. Notice produite par INIST-CNRS qMvdcR0x. Diffusion soumise à autorisation]. Objective. The goals of this study were to estimate seroprevalence of prior hepatitis B infection among high-risk adolescents and to determine the cost-effectiveness of prevaccination immunity screening. Methods. The authors computed a "break-even" seroprevalence level calculated from current vaccine and administration costs. They then conducted a seroprevalence study of hepatitis B core antibody using sera previously submitted for syphilis serology from four-hundred adolescent and adult clients of sexually transmitted disease clinics. Finally, the authors compared age group-specific seroprevalence rates to the computed break-even seroprevalence. Results. Levels of prior hepatitis B infection for all age groups were lower than the break-even seroprevalence standard from which cost-effectiveness was calculated. Conclusions. From the findings of this study, the authors concluded that routine preimmunization screening for prior hepatitis B infection would not be cost-effective for this population. |

